NCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
Clinical Trials
9 trialsNCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT03133988 2025-02-14
Margetuximab Expanded Access Program
TerSera Therapeutics LLC
Approved for marketing
NCT03906331 2025-01-17
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
Approved for marketing
NCT03763604 2024-12-16
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Eli Lilly and Company
Approved for marketing
NCT04395508 2022-07-05
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Genentech, Inc.
Approved for marketing
NCT04320693 2021-08-19
Expanded Access for IMMU-132
Gilead Sciences
Approved for marketing
NCT02792725 2017-10-31
Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Eli Lilly and Company
Approved for marketing
NCT01240421 2015-05-22
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Eisai Inc.
Approved for marketing